Prevention of PKG1α oxidation augments cardioprotection in the stressed heart.

The cGMP-dependent protein kinase-1α (PKG1α) transduces NO and natriuretic peptide signaling; therefore, PKG1α activation can benefit the failing heart. Disease modifiers such as oxidative stress may depress the efficacy of PKG1α pathway activation and underlie variable clinical results. PKG1α can also be directly oxidized, forming a disulfide bond between homodimer subunits at cysteine 42 to enhance oxidant-stimulated vasorelaxation; however, the impact of PKG1α oxidation on myocardial regulation is unknown. Here, we demonstrated that PKG1α is oxidized in both patients with heart disease and in rodent disease models. Moreover, this oxidation contributed to adverse heart remodeling following sustained pressure overload or Gq agonist stimulation. Compared with control hearts and myocytes, those expressing a redox-dead protein (PKG1α(C42S)) better adapted to cardiac stresses at functional, histological, and molecular levels. Redox-dependent changes in PKG1α altered intracellular translocation, with the activated, oxidized form solely located in the cytosol, whereas reduced PKG1α(C42S) translocated to and remained at the outer plasma membrane. This altered PKG1α localization enhanced suppression of transient receptor potential channel 6 (TRPC6), thereby potentiating antihypertrophic signaling. Together, these results demonstrate that myocardial PKG1α oxidation prevents a beneficial response to pathological stress, may explain variable responses to PKG1α pathway stimulation in heart disease, and indicate that maintaining PKG1α in its reduced form may optimize its intrinsic cardioprotective properties.

[1]  Akshay S. Desai,et al.  Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.

[2]  D. Kass,et al.  Phosphodiesterase 5 inhibition ameliorates angiontensin II-induced podocyte dysmotility via the protein kinase G-mediated downregulation of TRPC6 activity. , 2014, American journal of physiology. Renal physiology.

[3]  D. Kass,et al.  Hyperactive Adverse Mechanical Stress Responses in Dystrophic Heart Are Coupled to Transient Receptor Potential Canonical 6 and Blocked by cGMP–Protein Kinase G Modulation , 2014, Circulation research.

[4]  S. Solomon,et al.  The cGMP Signaling Pathway as a Therapeutic Target in Heart Failure With Preserved Ejection Fraction , 2013, Journal of the American Heart Association.

[5]  D. Kass,et al.  Nitric oxide synthases in heart failure. , 2013, Antioxidants & redox signaling.

[6]  F. Hofmann,et al.  Relaxins enhance growth of spontaneous murine breast cancers as well as metastatic colonization of the brain , 2011, Clinical & Experimental Metastasis.

[7]  P. Eaton,et al.  cGMP-Dependent Activation of Protein Kinase G Precludes Disulfide Activation: Implications for Blood Pressure Control , 2012, Hypertension.

[8]  Angela M. Lane,et al.  Protein Kinase G Iα Inhibits Pressure Overload–Induced Cardiac Remodeling and Is Required for the Cardioprotective Effect of Sildenafil In Vivo , 2012, Journal of the American Heart Association.

[9]  S. Dryer,et al.  Sustained Activation of N-Methyl-d-Aspartate Receptors in Podoctyes Leads to Oxidative Stress, Mobilization of Transient Receptor Potential Canonical 6 Channels, Nuclear Factor of Activated T Cells Activation, and Apoptotic Cell Death , 2012, Molecular Pharmacology.

[10]  Anindita Das,et al.  Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection. , 2012, Journal of the American College of Cardiology.

[11]  D. Kass,et al.  Pressure-Overload–Induced Subcellular Relocalization/Oxidation of Soluble Guanylyl Cyclase in the Heart Modulates Enzyme Stimulation , 2012, Circulation research.

[12]  P. Eaton,et al.  Single atom substitution in mouse protein kinase G eliminates oxidant sensing to cause hypertension , 2011, Nature Medicine.

[13]  J. Corbin,et al.  cGMP-Dependent Protein Kinases and cGMP Phosphodiesterases in Nitric Oxide and cGMP Action , 2010, Pharmacological Reviews.

[14]  K. Nakao,et al.  Inhibition of TRPC6 Channel Activity Contributes to the Antihypertrophic Effects of Natriuretic Peptides-Guanylyl Cyclase-A Signaling in the Heart , 2010, Circulation Research.

[15]  T. Yorio,et al.  Canonical Transient Receptor Potential 6 (TRPC6), a Redox-regulated Cation Channel* , 2010, The Journal of Biological Chemistry.

[16]  D. Kass,et al.  Cyclic GMP/PKG-dependent inhibition of TRPC6 channel activity and expression negatively regulates cardiomyocyte NFAT activation Novel mechanism of cardiac stress modulation by PDE5 inhibition. , 2010, Journal of molecular and cellular cardiology.

[17]  D. Kass,et al.  Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice. , 2009, The Journal of clinical investigation.

[18]  D. Kass,et al.  Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE 5 inhibition in mice , 2009 .

[19]  Yan Zhu,et al.  High blood pressure arising from a defect in vascular function , 2008, Proceedings of the National Academy of Sciences.

[20]  K. Nakao,et al.  Regulator of G-Protein Signaling Subtype 4 Mediates Antihypertrophic Effect of Locally Secreted Natriuretic Peptides in the Heart , 2008, Circulation.

[21]  A. Scholten,et al.  cGMP-binding prepares PKG for substrate binding by disclosing the C-terminal domain. , 2008, Journal of molecular biology.

[22]  E. Sundberg,et al.  Interactions between the leucine-zipper motif of cGMP-dependent protein kinase and the C-terminal region of the targeting subunit of myosin light chain phosphatase. , 2007, Journal of molecular biology.

[23]  J. P. Brennan,et al.  Cysteine Redox Sensor in PKGIa Enables Oxidant-Induced Activation , 2007, Science.

[24]  John McAnally,et al.  TRPC6 fulfills a calcineurin signaling circuit during pathologic cardiac remodeling. , 2006, The Journal of clinical investigation.

[25]  J. Stasch,et al.  Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. , 2006, The Journal of clinical investigation.

[26]  D. Kass,et al.  Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy , 2005, Nature Medicine.

[27]  R. Karas,et al.  Regulator of G-protein signaling-2 mediates vascular smooth muscle relaxation and blood pressure , 2003, Nature Medicine.

[28]  M. Wall,et al.  Mechanisms associated with cGMP binding and activation of cGMP-dependent protein kinase , 2003, Proceedings of the National Academy of Sciences of the United States of America.